Jazz Pharmaceuticals (NASDAQ:JAZZ) has acquired privately held clinical-stage biotech Cavion for up to $312.5M, consisting of $52.5M upfront and up to $260.0M in milestones.
Cavion’s lead candidate is small molecule CX-8998, in Phase 2 development for essential tremor and absence epilepsy.
Management will host a conference call at 5:00 pm ET to discuss the deal.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.